Lotus Pharmaceutical Statistics

Total Valuation

Lotus Pharmaceutical has a market cap or net worth of TWD 67.76 billion. The enterprise value is 75.57 billion.

Market Cap	67.76B
Enterprise Value	75.57B

Important Dates

The next estimated earnings date is Friday, November 8, 2024.

Earnings Date	Nov 8, 2024
Ex-Dividend Date	Aug 5, 2024

Share Statistics

Lotus Pharmaceutical has 265.19 million shares outstanding. The number of shares has increased by 0.40% in one year.

Shares Outstanding	265.19M
Shares Change (YoY)	+0.40%
Shares Change (QoQ)	+0.10%
Owned by Insiders (%)	0.65%
Owned by Institutions (%)	6.42%
Float	158.58M

Valuation Ratios

The trailing PE ratio is 16.73 and the forward PE ratio is 13.32.

PE Ratio	16.73
Forward PE	13.32
PS Ratio	3.95
PB Ratio	3.66
P/FCF Ratio	18.65
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 12.75, with an EV/FCF ratio of 20.80.

EV / Earnings	18.83
EV / Sales	4.46
EV / EBITDA	12.75
EV / EBIT	16.10
EV / FCF	20.80

Financial Position

The company has a current ratio of 2.16, with a Debt / Equity ratio of 0.58.

Current Ratio	2.16
Quick Ratio	1.51
Debt / Equity	0.58
Debt / EBITDA	1.80
Debt / FCF	2.94
Interest Coverage	8.28

Financial Efficiency

Return on equity (ROE) is 23.68% and return on invested capital (ROIC) is 10.54%.

Return on Equity (ROE)	23.68%
Return on Assets (ROA)	8.85%
Return on Capital (ROIC)	10.54%
Revenue Per Employee	15.41M
Profits Per Employee	3.65M
Employee Count	1,099
Asset Turnover	0.51
Inventory Turnover	1.99

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +11.21% in the last 52 weeks. The beta is 0.52, so Lotus Pharmaceutical's price volatility has been lower than the market average.

Beta (5Y)	0.52
52-Week Price Change	+11.21%
50-Day Moving Average	269.86
200-Day Moving Average	285.09
Relative Strength Index (RSI)	38.95
Average Volume (20 Days)	1,465,150

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Lotus Pharmaceutical had revenue of TWD 16.93 billion and earned 4.01 billion in profits. Earnings per share was 15.27.

Revenue	16.93B
Gross Profit	9.25B
Operating Income	4.69B
Pretax Income	5.04B
Net Income	4.01B
EBITDA	5.80B
EBIT	4.69B
Earnings Per Share (EPS)	15.27

Full Income Statement

Balance Sheet

The company has 2.86 billion in cash and 10.67 billion in debt, giving a net cash position of -7.81 billion or -29.46 per share.

Cash & Cash Equivalents	2.86B
Total Debt	10.67B
Net Cash	-7.81B
Net Cash Per Share	-29.46
Equity (Book Value)	18.48B
Book Value Per Share	69.72
Working Capital	7.62B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 4.07 billion and capital expenditures -437.91 million, giving a free cash flow of 3.63 billion.

Operating Cash Flow	4.07B
Capital Expenditures	-437.91M
Free Cash Flow	3.63B
FCF Per Share	13.70

Full Cash Flow Statement

Margins

Gross margin is 54.64%, with operating and profit margins of 27.72% and 23.70%.

Gross Margin	54.64%
Operating Margin	27.72%
Pretax Margin	29.77%
Profit Margin	23.70%
EBITDA Margin	34.28%
EBIT Margin	27.72%
FCF Margin	21.46%

Dividends & Yields

This stock pays an annual dividend of 4.65, which amounts to a dividend yield of 1.84%.

Dividend Per Share	4.65
Dividend Yield	1.84%
Dividend Growth (YoY)	34.32%
Years of Dividend Growth	3
Payout Ratio	22.58%
Buyback Yield	-0.40%
Shareholder Yield	1.44%
Earnings Yield	5.98%
FCF Yield	5.36%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Lotus Pharmaceutical has an Altman Z-Score of 4.29.

Altman Z-Score	4.29
Piotroski F-Score	n/a